Kerala CM's programme in Malappuram postponed following Nipah case
Besides the CM's programme, an anti-drug campaign scheduled to be held in the district on Saturday, under the leadership of the State Minister for Sports V Abdurahiman, has also been postponed to another date in view of the Nipah virus infection.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
3 days ago
- Mint
India's drug regulator plans overhaul of Schedule H for prescription medicines
New Delhi: Drugs Controller General of India (DCGI), the country's top drug regulator, is planning a complete overhaul of medicines listed under Schedule H of the Drugs and Cosmetics Rules, 1945, which governs the sale of prescription drugs, said an official aware of the matter and documents reviewed by Mint. Also Read | Key drugs, diagnostics run short in public health centres, govt raises alarm The proposed revamp is driven by concerns, including a rise in antimicrobial resistance (AMR) from self-medication and rampant use of antibiotics purchased over the counter without prescription, the official said. Schedule H includes drugs that cannot be purchased or sold on retail without a doctor's prescription. This overhaul will involve updating the list of prescription drugs by incorporating new medicines and formulations that have been introduced in the market in the recent past. 'The issue related to making suitable reforms in the drug regulatory system has been in discussion for quite some time now. The exercise is part of India's fight against irrational use of antimicrobial medicines, which are used to prevent and treat infectious diseases in humans, animals and plants, including antibiotics, antivirals, antifungals and antiparasitics," said the official on the condition of anonymity. Also Read | What America has got wrong about gender medicine In 2022, a high-level expert committee was constituted by the health ministry to review and revise Schedule H Drugs to recommend comprehensive changes in the drug regulatory regime to reflect global best practices as well as domestic requirements. Remdesivir, dexamethasone, favipiravir, ivermectin and mebrofenin are some of the drugs that are proposed to be added to Schedule H. Right now, there are around 536 drugs under Schedule H. The committee had discussed the existing regulatory framework in detail and noted that the drugs that are not included in Schedule G, H, H1 and X can be easily sold in the country without prescription of a Registered Medical Practitioner (RMP) and it is 'not in public interest", according to the documents reviewed by Mint. Also Read | ICMR gets a breakthrough in attempts to develop first indigenous Nipah virus medicine 'There are many drugs used for various indications like diabetes, TB, heart disease, pain killers etc which are put in special categories like anti-diabetic, anti-pain relief, anti-depressants, anticoagulant drugs, and cardiovascular drugs of the Drug Rule. However, these drugs should fall in schedule H. So, efforts are being made to streamline this," said the official. The expert panel recommended a revamp of the Schedule H. 'Schedule H includes drugs of various categories which require prescription of RMP for their retail sale. The Schedule H needs to be updated regularly to incorporate the new drugs introduced in the market from time to time as well as to review the prescription status of different drugs in the present context. Such regular updates are crucial in the current context to address various regulatory challenges leading to irrational use of drugs, including antibiotics and development of anti-microbial resistance," the documents showed. Wrong or over-use of these medicines can lead to the emergence of antimicrobial resistance (AMR), which is hard to treat and can cause further infections. The committee has proposed more than 700 drugs to be added to the Schedule H drugs list in addition to the existing drugs, as per the documents. The committee also reviewed various aspects of the drugs like their indication, route of administration, international prescription status, abuse or misuse potential, human/ veterinary use, therapeutic/ prophylactic usage etc. When the committee reviewed Schedule G, it opined that drugs mentioned under this list bear caution that 'it is dangerous to take this medicine except under medical supervision". While Schedule G drugs carry a strong caution about medical supervision, the rules governing their sale did not, in the past, explicitly mandate an RMP prescription for every single sale, unlike Schedule H drugs. The committee has recommended the addition of several categories of drugs, namely cardiovascular drugs, neurological drugs, respiratory drugs, anesthetic drugs, antiemetic drugs, immunological drugs, genito-urinary drugs, non-steroidal anti-inflammatory drug, and all sterile formulations of any drug to schedule H.
Time of India
4 days ago
- Time of India
Viral truths
Covid's return not a big worry. But a case in Delhi HC shows what's worrying when it comes to outbreaks It is safe to assume that had Delhi HC not issued a notice to Centre for failing to present in court minimum standards for sample collection, most wouldn't have known that India has no SOP mandated for diagnostic labs. Protocols of course exist, but SOPs are not mandatory. This case has gained traction given the rise in Covid cases. Delhi HC sounded a note of caution. This is despite the fact that GOI, epidemiologists and medical fraternity all agree that given the endemicity of Covid and that almost 70% of the population is fully vaccinated, this round of Covid is little more than 'seasonal flu'. There is no cause for worry. But that is not to say now is not the time for the whole preparedness-shebang to kick in – from wearing masks to surveilling the spread with more testing. Cases are climbing, as are deaths. All deaths have been of those with Covid, not of Covid. Point is, India's burden of comorbidity is massive – diabetes to TB to COPD, chronic kidney disease, and cancer patients & survivors. Against this reality, it's hard to see why Union health ministry wasn't more proactive to Delhi HC's 2023 order to formulate minimum standards for sample collection. It is not about Covid alone. Our healthcare systems must brace for viral outbreaks at any point given the two major challenges today – a dizzying number of dangerous viruses (H5N1, dengue, chikungunya, Nipah, Zika are household terms) and antibiotic-resistant bacteria. Preparedness and quick response make healthcare systems more resilient. Govt estimates put Covid deaths at 5.3L. Lessons were learned. Every weak link in public health machinery was exposed. In the three years since, how many of these weaknesses have been fixed? Is surveillance better? Is the expanded virus research & diagnostic laboratory network fully equipped? Variant identification took a long time during the pandemic. Have we fixed that? Surveillance systems, healthcare infra and community engagement ensure public health. Covid may not be a threat, but as epidemiologist Gagandeep Kang put it: 'What we know we don't know is when, where and what our next disease outbreak will be.' An SOP for sample collection and transport seems to be the very least govt can do. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
Time of India
4 days ago
- Time of India
AIIMS Nagpur is Maharashtra's first medical college to get BSL-3 lab
Nagpur: In a significant step forward for public health in Vidarbha and surrounding areas, AIIMS Nagpur will soon be home to Maharashtra's first Bio-Safety Level-3 (BSL-3) laboratory in a medical college, thanks to a tie-up with the National Centre for Disease Control (NCDC), New Delhi. This cutting-edge lab will help doctors quickly detect and respond to deadly infections like Nipah, Zika, bird flu, and even viruses used in bioterrorism. For common people, this means faster diagnosis, better protection during disease outbreaks, and stronger health systems in our region. "This BSL-3 lab will make AIIMS Nagpur a hub for detecting dangerous infections early, which is crucial to stop them from spreading," said Dr Prashant P Joshi, executive director of AIIMS Nagpur. Currently, the only BSL-3 lab in Maharashtra is at the National Institute of Virology, Pune. Once operational, the Nagpur lab will not only serve patients but will also train microbiologists and technicians from across the state to fight infectious diseases better. Dr Meena Mishra, who heads the department of microbiology and is the project in charge, explained, "BSL-3 labs are highly secure and are built to handle very dangerous germs. These germs can cause severe disease and can spread from animals to humans, like Japanese Encephalitis, Mpox, or Nipah virus. With this lab, we'll be able to test and research them safely right here in Nagpur." Unlike the existing BSL-2 lab at AIIMS, which handles common infections like dengue and Covid-19, the BSL-3 lab will work with much riskier pathogens. It will have features like airtight rooms, HEPA filters to clean the air, and specially trained staff in full protective gear. The lab is being set up under the PM-Ayushman Bharat Health Infrastructure Mission. The NCDC has allotted Rs30 crore for it — Rs25 crore for infrastructure and Rs5 crore for equipment and testing kits. Experts from Delhi, including Sunil Bharadwaj (additional director, NCDC), Dr Ankur Garg (joint director), and Dr Aradhana Bhargava (nodal officer for the lab), recently signed the MoU with AIIMS authorities during their visit to Nagpur. Once ready, this BSL-3 lab will become a crucial defence system against any future epidemic or bio-emergency, ensuring that people in Central India don't have to wait or travel far for testing and treatment. "This initiative strengthens India's ability to deal with public health emergencies. We're proud to bring such a facility to Nagpur," Dr Joshi added.
